Abstract: FR-PO0203
Haematologic Effects of Long-Term Daprodustat in Patients on Maintenance Hemodialysis: A Three-Year Evaluation
Session Information
- Anemia and Iron Metabolism
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Anemia and Iron Metabolism
- 200 Anemia and Iron Metabolism
Authors
- Morii, Kenichi, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Hiroshima Prefecture, Japan
- Doi, Toshiki, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Hiroshima Prefecture, Japan
- Nishizawa, Yoshiko, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Hiroshima Prefecture, Japan
- Yamashita, Kazuomi, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Hiroshima Prefecture, Japan
- Mizuiri, Sonoo, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Hiroshima Prefecture, Japan
- Masaki, Takao, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima Prefecture, Japan
Background
Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates endogenous erythropoietin production and improves iron metabolism by suppressing hepcidin levels. While clinical trials have demonstrated its short- to mid-term efficacy and safety in dialysis patients, data on long-term hematologic stability and sustainability of response beyond two years remain limited. This study aims to evaluate the effects of three-year daprodustat treatment on hemoglobin levels, red blood cell indices, and iron-related parameters in patients undergoing maintenance hemodialysis.
Methods
This observational study included 33 maintenance hemodialysis patients who switched from erythropoiesis-stimulating agents to daprodustat at our affiliated facilities between December 2019 to December 2021. Hematologic parameters (RBC, Hb, Ht, MCV, MCH, MCHC, RDW-CV, serum iron, TSAT, and ferritin) were assessed at baseline, 0.5, 1, and 3 years.
Results
During the three-year observation period, five patients died and three were transferred to other facilities, resulting in 25 patients being included in the analysis. No significant differences in RBC, Hb, or Ht levels were observed when comparing baseline with values at 0.5, 1, and 3 years. MCV showed a substantial increase at years 1 and 3, while MCH and MCHC significantly increased at 0.5, 1, and 3 years compared to baseline (P < 0.05). RDW-CV significantly decreased at 0.5, 1, and 3 years (P < 0.05). Serum iron and TSAT levels increased substantially at years 1 and 3 (P < 0.05), whereas ferritin levels showed no significant change.
Conclusion
Three-year treatment with daprodustat maintained stable RBC, Hb, and Ht levels in patients on maintenance hemodialysis. Changes in MCV, MCH, and MCHC and a reduction in RDW-CV suggest favorable modulation of erythrocyte indices. Additionally, increased serum iron and TSAT without a rise in ferritin indicate enhanced iron utilization without iron overload.